Immune System Key Ltd.

Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
It is engaged in discovery and development of innovative treatments for malignant and autoimmune diseases with strong unmet needs. ISK’s assets are based on novel human secreted peptides, which were discovered by the founders. ISK’s lead compound is NerofeTM. NerofeTM was granted by the FDA with orphan drug status for AML treatment and currently is in phase IIa development stage. The company holds 3 worldwide patents on the molecule and applications.

LATEST NEWS

Advancing Cancer Treatment with Enhanced Nerofe

31 Mar|Comments Off on Advancing Cancer Treatment with Enhanced Nerofe

ISK is proud to announce a significant development in our ongoing commitment to cancer research and treatment. We have successfully developed and are now in the process of filing a patent for an enhanced form of Nerofe, our proprietary cancer treatment.

This advancement represents a major milestone in our mission to combat cancer. The enhanced form of Nerofe has shown promising potential in preclinical studies, demonstrating our continuous innovation in the field of oncology.

We remain dedicated to our mission of improving patient outcomes and will continue to share updates on the progress of this exciting development. Thank you for your continued support.

  • youtube video

Dr. Devary: Transforming “Cold Tumors” into “Hot Tumors”: Nerofe and DOX Synergy against KRAS Mutations

26 Oct|Comments Off on Dr. Devary: Transforming “Cold Tumors” into “Hot Tumors”: Nerofe and DOX Synergy against KRAS Mutations

  • combined_seal

Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal

18 Dec|Comments Off on Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal

ISK is excited to report the official opening of its second FDA approved clinical trial in the US in patients with pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.

IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track

29 Nov|Comments Off on IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track

Following FDA approval to open our trial at Georgetown University in Washington DC, we received final IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track

New Nerofe Formulation for treatment of Stage 4 squamous cell lung cancer

29 Nov|Comments Off on New Nerofe Formulation for treatment of Stage 4 squamous cell lung cancer

Using a new formulation of Nerofe, treating a patient with Stage 4 squamous cell lung cancer (positive for ST2), caused the complete disappearance of some tumors and a decrease in the size of other tumors. Increase in hepatic function.

New Nerofe Formulation for treatment of adenocarcinoma in the anus with metastasis in the peritoneum

29 Nov|Comments Off on New Nerofe Formulation for treatment of adenocarcinoma in the anus with metastasis in the peritoneum

Using a new formulation of Nerofe on a patient (positive for ST2) with adenocarcinoma in the anus and two metastasis in the peritoneum caused the complete disappearance of tumors.